ANI Pharmaceuticals announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug Fleqsuvy. U.S. annual sales for Baclofen Oral Suspension total approximately $39M, according to IQVIA data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
- ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
- ANI Pharmaceuticals announces launch of Levofloxacin Oral Solution
- ANI Pharmaceuticals initiated with an Overweight at Capital One
